Market Intelligence, Clinical Progress, and High-Purity Reagents for Hematologic and Rare Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for XK drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | XK Recombinant Protein Sequence Verified. High Purity (>95%). HEK293 Expressed (Native Glycosylation). Endotoxin Controlled. |
View XK Products |
| Gene Delivery | XK Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Conformation preserved for cell-based assays. |
View XK Products |
| Benchmark Ab | Anti-XK Antibody Recombinant positive control for assay validation. |
View XK Products |
| Validator | XK siRNA Set For knockdown verification and specificity controls. |
View XK Products |
| Related Target A | KEL (Kell Metallo-endopeptidase) Covalently links with XK via disulfide bonds to form the Kell-XK complex; critical for structural integrity. |
View KEL Products |
| Related Target B | CD47 Interacts with the Kell-XK complex within the erythrocyte membrane skeleton network. |
View CD47 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass membrane protein conformation preservation | Lentivirus Premade Particles for stable cell line expression, avoiding unstable detergent-solubilized proteins. |
| Epitope mapping for rare disease therapeutics | Sequence Verified, high-purity recombinant extracellular loops for precise binding assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live XK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for XK therapeutics is intensifying, with major players shifting focus from traditional mAbs to gene therapies and advanced cell-surface targeting modalities. As first-generation therapies for McLeod syndrome and associated hematological disorders reach the clinic, the next wave of R&andD is targeting the complex interaction of the Kell-XK system on red blood cells and its role in immune-mediated clearance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV/Lentivirus) | Academic Medical Centers, Biotech Startups | McLeod Syndrome, Acanthocytosis | Transfection Validation (Need Lentivirus for Stable Cell Line) |
| Monoclonal Antibodies (mAbs) | Biopharma Innovators | Autoimmune Hemolytic Anemia | Conformational Binding (Need Cell-based Flow Cytometry) |
| Small Molecules / Chaperones | Rare Disease Specialists | Red Blood Cell Membrane Stability | Complex Assembly Screening (Need XK & KEL Co-expression) |